Skip to content

RheumaFinder is an AI-powered application that detects rheumatic diseases on a range of radiological imaging modalities

Developed for the early detection of rheumatic diseases, RheumaFinder can detect hallmark lesions even before patients experience any clinical symptoms. Moreover, RheumaFinder can detect patients with rheumatic diseases who otherwise would have never been diagnosed. Cloud native and PACS-agnostic, RheumaFinder will be implemented as an add-on application to any type of PACS, opening up new possibilities for higher diagnostic pickup rates and early detection and treatment of rheumatic disease with improved patient and societal outcomes.

RheumaFinder software seamlessly integrates on any PACS
RheumaFinder software
seamlessly integrates
on any PACS
RheumaFinder software
has detected signs
of rheumatic disease

Early detection of rheumatic diseases
in medical imaging

Artificial Intelligence (AI) can be used to detect lesions and discover new imaging biomarkers for early diagnosis and prevention of diseases. In this way, more precise disease monitoring and follow-up is enabled, providing an extra layer of image interpretation and useful information.

Frequently, in medical images obtained for other diagnostic questions, incidental findings are present. Despite being detectable in the images, they are often not picked up due to their subtle appearance and foremost time constraints in the clinical practice. Preventive early detection of disease can be achieved when the power of AI is used as an extra pair of eyes to support radiologists in the background.

AI is being used in radiology in a number of ways today. However, deep learning algorithms have not yet been applied in real-world imaging into applicable use cases in imaging of structural joint damage caused by inflammation in rheumatic diseases. For the most effective use of AI, it is necessary to coordinate the input of high-quality expert-labelled medical images and algorithm development between physicians and computer scientists. These use cases can solve increasingly challenging problems in clinical practice. This (r)evolution in imaging depends on applying powerful AI tools to clinical problems in the best possible ways, i.e., the successful development of AI use cases.

Early diagnosis and treatment of rheumatic diseases can prevent irreversible structural lesions of the joints and disability thus improving quality of life in these very common diseases

Developed for the (early) detection of rheumatic diseases, the RheumaFinder application is an AI-powered add-on to your PACS that may detect disease, even before patients themselves are aware of any symptoms. Moreover, it can detect inflammatory joint damage on a range of medical imaging techniques as incidental finding in examinations that are performed for other diagnostic questions. 

The RheumaFinder software uses advanced AI to analyse medical images for (early) signs of the disease. We develop algorithms envisioning eight major groups of use cases. Exceptional high-quality labelling of international datasets resulted in unsurpassed results (90% of all patients with detectable and important lesions are identified in the proof-of-concept of our first use cases). 

As cloud native solution, RheumaFinder will integrate the power, speed and flexibility of cloud computing. RheumaFinder will be implemented as an add-on to any type of PACS, quickly and easily. Available as a Software-as-a-Service, in a customer-tuned pay-per-use model with multiple classification categories, the efficacy of these algorithms in clinical practice will be supported by significant scientific and clinical validation studies from across Europe, the US and Canada, fully compliant with GDPR and HIPAA privacy regulations.

AI detected hallmark findings (inflammation/structural lesions) are highlighted

Patient journey

Millions of people could get an early diagnosis

As rheumatic diseases are today not screened for and often remain undetected until irreversible major damage occurs, its early flagging will drastically improve the patient quality of life, reduce healthcare costs and improve decision making in the therapeutic journey.


RheumaFinder Announces Investment By Novalis Biotech

RheumaFinder Announces Investment by Novalis Biotech

12 February 2024

Februari 2024 – RheumaFinder is excited to announce an investment from Belgium’s Novalis Biotech Acceleration Fund. This investment, executed as…

New Offices At The Watt Factory In Ghent

New offices at the Watt Factory in Ghent

16 December 2023

New offices at the Watt Factory in Ghent The RheumaFinder team has moved to new offices at the Watt Factory…

RheumaFinder’s Study On Validating The Diagnostic Accuracy Of AI Detecting Hallmark Lesions Gets Published In European Radiology

RheumaFinder’s study on validating the diagnostic accuracy of AI detecting hallmark lesions gets published in European Radiology

26 May 2023

Dr. Thomas Van Den Berghe’s recent study called “Neural network algorithm for detection of erosions and ankylosis on CT of…

Fund For Scientific Research In Rheumatology (FWRO/FRSR)

Fund for Scientific Research in Rheumatology (FWRO/FRSR)

16 September 2022

Fund for Scientific Research in Rheumatology (FWRO/FRSR) Prof. Dr. Lennart Jans of RheumaFinder has been named as a recipient from…

Interview By The Leading Online Newspaper Medscape

Interview by the leading online newspaper Medscape

16 September 2022

Interview by the leading online newspaper Medscape Prof. Dr. Lennart Jans was interviewed by the leading online newspaper Medscape at…

Annual Scientific Meeting Of The European Alliance Of Associations For Rheumatology (EULAR) Copenhagen

Annual scientific meeting of the European Alliance of Associations for Rheumatology (EULAR) Copenhagen

16 September 2022

At the annual scientific meeting of the European Alliance of Associations…

European Society Of Musculoskeletal Radiology Young Researcher Grant 2022

European Society of Musculoskeletal Radiology Young Researcher Grant 2022

17 August 2022

Very grateful and proud to announce that our Chief Science Officer, Thomas Van Den Berghe…

Back To Top